Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4142375 | 0.91 | TSHR (0.34) | TSHRNFKB1CYP2C19 | |
| SCHEMBL21517924 | 0.88 | TSHR (0.33) | TSHRNFKB1CYP2C19 | |
| SCHEMBL28586980 | 0.88 | TSHR (0.33) | TSHRNFKB1CYP2C19 | |
| SCHEMBL15525247 | 0.88 | TSHR (0.33) | TSHRNFKB1CYP2C19 | |
| Methylamine SCHEMBL23410411 | 0.86 | TSHR (0.32) | TSHRNFKB1CYP2C19 | |
| SCHEMBL28349565 | 0.86 | TSHR (0.32) | TSHRNFKB1CYP2C19 | |
| Magnesium Chloride Anhydrous SCHEMBL28609893 | 0.81 | TSHR (0.30) | TSHRNFKB1CYP2C19 | |
| SCHEMBL16236606 | 0.76 | — | — | |
| Methacrylic Acid SCHEMBL28774452 | 0.71 | TSHR (0.40) | TSHRNFKB1CYP2C19 | |
| Acrylic Acid SCHEMBL27814354 | 0.71 | TSHR (0.40) | TSHRNFKB1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4387957-A1 | FUNGICIDAL SUBSTITUTED HETEROCYCLES | FMC Corporation (US) | 2024-06-26 | — | — | EP | disclosed |
| WO-2024105553-A1 | BICYCLIC HETEROCYCLES AND THEIR USE AS WRN INHIBITORS | NOVARTIS AG (CH) | 2024-05-23 | — | — | WO | disclosed |
| EP-4347596-A1 | TRIAZOLO-PYRIMIDINE ANALOGUES FOR TREATING DISEASES CONNECTED TO THE INHIBITON OF WERNER SYNDROME RECQ HELICASE (WRN) | Novartis AG (CH) | 2024-04-10 | — | — | EP | disclosed |
| US-11878973-B2 | Bicyclic compounds and their uses | NOVARTIS AG (CH) | 2024-01-23 | — | — | US | disclosed |
| US-20230095836-A1 | SUBSTITUTED 5,6-DIPHENYL-3(2H)-PYRIDAZINONES FOR USE AS FUNGICIDES | FMC CORPORATION | 2023-03-30 | — | — | US | disclosed |
| WO-2023023242-A1 | FUNGICIDAL SUBSTITUTED HETEROCYCLES | FMC CORPORATION (US) | 2023-02-23 | — | — | WO | disclosed |
| US-20230046859-A1 | Bicyclic Compounds and their Uses | NOVARTIS PHARMA AG (CH) | 2023-02-16 | — | — | US | disclosed |
| EP-4103554-A1 | SUBSTITUTED 5,6-DIPHENYL-3(2H)-PYRIDAZINONES FOR USE AS FUNGICIDES | FMC CORPORATION (US) | 2022-12-21 | — | — | EP | disclosed |
| WO-2022249060-A1 | TRIAZOLO-PYRIMIDINE ANALOGUES FOR TREATING DISEASES CONNECTED TO THE INHIBITON OF WERNER SYNDROME RECQ HELICASE (WRN) | NOVARTIS AG (CH) | 2022-12-01 | — | — | WO | disclosed |
| WO-2021163519-A1 | SUBSTITUTED 5,6-DIPHENYL-3(2H)-PYRIDAZINONES FOR USE AS FUNGICIDES | FMC CORPORATION (US) | 2021-08-19 | — | — | WO | disclosed |
| CN-105899507-B | Aryl sultam derivative as RORc regulator | 豪夫迈·罗氏有限公司 | 2019-06-07 | — | — | CN | disclosed |
| US-10259808-B2 | Aryl sultam derivatives as RORc modulators | GENENTECH, INC. (US) | 2019-04-16 | — | — | US | disclosed |
| US-20180263996-A1 | ARYL SULTAM DERIVATIVES AS RORc MODULATORS | GENENTECH, INC. (US) | 2018-09-20 | — | — | US | disclosed |
| EP-3319962-A1 | ARYL SULTAM DERIVATIVES AS RORc MODULATORS | H. Hoffnabb-La Roche Ag (CH) | 2018-05-16 | — | — | EP | disclosed |
| US-20180118683-A1 | INDOLONE COMPOUNDS AND THEIR USE AS AMPA RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-05-03 | — | — | US | disclosed |
| US-20180105516-A1 | ARYL SULTAM DERIVATIVES AS RORc MODULATORS | GENENTECH, INC. (US) | 2018-04-19 | — | — | US | disclosed |
| WO-2017005668-A1 | ARYL SULTAM DERIVATIVES AS RORc MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2017-01-12 | — | — | WO | disclosed |
| WO-2017005900-A1 | ARYL SULTAM DERIVATIVES AS RORc MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2017-01-12 | — | — | WO | disclosed |
| CN-105899507-A | Aryl sultam derivatives as rorc modulators | 豪夫迈·罗氏有限公司 | 2016-08-24 | — | — | CN | disclosed |
| WO-2014031971-A1 | HERBICIDAL PYRIDAZINONES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2014-02-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180105516-A1 | ARYL SULTAM DERIVATIVES AS RORc MODULATORS | RORC, RORB, RORA | TSHR 490/4885NFKB1 736/4885CYP2C19 232/4885 |
| US-11878973-B2 | Bicyclic compounds and their uses | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, C1R, F12 | TSHR 1331/4885NFKB1 2230/4885CYP2C19 435/4885 |
| US-20230095836-A1 | SUBSTITUTED 5,6-DIPHENYL-3(2H)-PYRIDAZINONES FOR USE AS FUNGICIDES | PNPO, CBR3, CYP2D6 | TSHR 2948/4885NFKB1 1273/4885CYP2C19 89/4885 |
| US-20180263996-A1 | ARYL SULTAM DERIVATIVES AS RORc MODULATORS | RORC, RORA, RORB | TSHR 368/4885NFKB1 922/4885CYP2C19 396/4885 |
| US-20230046859-A1 | Bicyclic Compounds and their Uses | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, C1R, F12 | TSHR 1331/4885NFKB1 2230/4885CYP2C19 435/4885 |
| US-10259808-B2 | Aryl sultam derivatives as RORc modulators | RORC, RORB, RORA | TSHR 490/4885NFKB1 736/4885CYP2C19 232/4885 |
| US-20180118683-A1 | INDOLONE COMPOUNDS AND THEIR USE AS AMPA RECEPTOR MODULATORS | GRIN3A, GRIN1, GRIN2B | TSHR 446/4885NFKB1 2930/4885CYP2C19 485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.